Artificial Intelligence

CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.

Risk management and the need for back-up systems are fast emerging as themes that users of artificial intelligence tools in health care settings must face up to. Now more comfortable with the technology’s capabilities, health care stakeholders appreciate that there can be two sides to the AI coin.

Medtech Insight brings you the highlights from two panel discussions at CES 2025 featuring innovators in the neurotech space discussing opportunities, challenges and ethical considerations in developing AI-driven solutions for the brain, and what lies ahead.

Medtech Insight spoke with René Quashie, vice president of digital health at the Consumer Technology Association (CTA), about what to expect at this year’s CES show.

In this week’s Digital Health Roundup, Medtech Insight’s Marion Webb brings highlights from Deloitte’s 2025 Life Sciences Outlook Report with medtech leaders’ forecasting significant investments in AI/GenAI. Brian Bossetta talks about the US FDA’s newly formed Digital Health Advisory Committee. Elizabeth Orr highlights the pros and cons of penetration testing for cybersecurity and talks about the US FDA’s final guidance on pre-determined change control plans. Natasha Barrow highlights UK MHRA's AI Airlock Pilot program and MANIFEST.

An artificial intelligence-based pathology tool for metabolic dysfunction-associated steatohepatitis shows promise for a drug development landscape that is said to be “fraught with trials that have shown borderline results or outright failures based on liver histology.”

The ability of artificial intelligence tools to distinguish correlation from causation could prove to be a boon to the industry.

France’s medtech sector is strong, growing and innovative. In Vivo spoke to several French medtech leaders about the unique features and pitfalls their industry may face.

Pharmaceutical manufacturers face unique challenges, particularly when it comes to managing thousands of complex rebate contracts and connecting the dots between contract agreements and business performance.

Merck’s India head for process solutions and Aragen Bioscience’s CEO talk about an incubator set-up and AI-led drug discovery to enable India’s research ecosystem, US tariffs on China, ADC and GLP-1 development, funding path for Goldman Sachs-investee Aragen and more in this video interview